Targeted therapy represents one of the most significant developments in modern oncology, offering a more precise approach to cancer treatment than traditional chemotherapy. By focusing on specific molecular features that drive cancer growth, targeted therapies aim to improve effectiveness while reducing unnecessary damage to healthy cells.
As cancer care increasingly moves toward personalised medicine, targeted therapy has become a key option across many treatment pathways, including those followed within the UK’s National Health Service and international specialist centres.
What Is Targeted Therapy?
Targeted therapy refers to a class of cancer treatments designed to interfere with specific genes, proteins, or cellular pathways that allow cancer cells to grow and survive. These targets are identified through laboratory analysis of tumour tissue or blood samples, often using molecular and genetic testing.
Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapy is designed to act selectively on cancer-related mechanisms. This distinction often results in fewer systemic side effects and allows treatment to be tailored to the biological characteristics of each patient’s disease.
Further clinical explanation of how Targeted therapy works can be found through international oncology reference centres that specialise in precision-based treatment models.
How Targeted Therapy Differs from Chemotherapy
Chemotherapy remains an important treatment for many cancers, but its non-specific action can lead to side effects such as fatigue, nausea, hair loss, and immune suppression. Targeted therapies work at a molecular level, meaning their effects are often more contained.
For some patients, this translates into better tolerance and improved quality of life during treatment. In the UK, targeted therapies are increasingly used either alone or in combination with other treatments, depending on tumour type, stage, and molecular profile.
Targeted Therapy in Breast Cancer Care
Breast cancer treatment has been particularly transformed by targeted therapy. Tumours are now routinely classified by molecular markers such as hormone receptor status and HER2 expression, which directly influence treatment decisions.
HER2-positive breast cancers, for example, may be treated with drugs that block HER2 signalling pathways, significantly improving outcomes. Hormone receptor-positive cancers may be managed with therapies that suppress oestrogen activity, in some cases reducing the need for chemotherapy altogether.
These approaches are widely incorporated into UK oncology practice and supported by national clinical guidelines.
Precision Diagnostics and Treatment Selection
The effectiveness of targeted therapy depends on accurate diagnostic testing. Tumour profiling using immunohistochemistry and genomic analysis helps clinicians identify which treatments are likely to be beneficial.
This diagnostic-driven approach reduces unnecessary exposure to ineffective therapies and supports more individualised care plans — a principle increasingly emphasised across UK cancer services.
Beyond Breast Cancer
Targeted therapies are also used in the treatment of lung cancer, colorectal cancer, melanoma, and certain blood cancers. Treatments aimed at molecular drivers such as EGFR, ALK, and BRAF are now part of standard care pathways in many oncology centres.
As research advances, the range of cancers eligible for targeted treatment continues to expand.
Living With Targeted Therapy
Targeted treatments may be administered orally or intravenously, depending on the medication. Patients are monitored through imaging and laboratory testing to assess response and manage side effects early.
This ongoing monitoring supports long-term disease control and helps clinicians adjust treatment as required — an approach consistent with chronic disease management models increasingly used in oncology.
The Future of Cancer Treatment
Ongoing research continues to refine targeted therapy, with new drugs and combinations emerging as scientific understanding of cancer biology evolves. Precision medicine is now a central focus of cancer research globally, including within the UK.
By combining advanced diagnostics with evidence-based treatment selection, targeted therapy reflects a broader shift toward more personalised, patient-centred cancer care.
